Published in J Lab Clin Med on March 01, 1970
A randomized controlled trial of aspirin in the prevention of early mortality in myocardial infarction. J R Coll Gen Pract (1979) 1.06
The interaction of varying doses of dipyridamole and acetyl salicylic acid on the inhibition of platelet functions and their effect on bleeding time. Br J Clin Pharmacol (1979) 1.03
Inhibition of platelet release reaction by acetylsalicylic acid. Postgrad Med J (1976) 0.86
Platelets, aspirin, and cardiovascular disease. Postgrad Med J (1998) 0.80
The effect of aspirin on rebleeding in traumatic hyphema. Trans Am Ophthalmol Soc (1976) 0.76
Comparative evaluation of antiplatelet effect of lycopene with aspirin and the effect of their combination on platelet aggregation: An in vitro study. Indian J Pharmacol (2016) 0.75
Experimental evaluation of analgesic, anti-inflammatory and anti-platelet potential of Dashamoola. J Ayurveda Integr Med (2015) 0.75
Fatal disseminated candidiasis due to amphotericin-B-resistant Candida guilliermondii. Ann Intern Med (1985) 1.84
Electronic clinical trial protocol distribution via the World-Wide Web: a prototype for reducing costs and errors, improving accrual, and saving trees. J Am Med Inform Assoc (1997) 1.41
Locally advanced breast cancer in Saudi Arabia: high frequency of stage III in a young population. Med Oncol (1999) 1.33
Antigenic analysis of hematopoiesis. V. Characterization of My-10 antigen expression by normal lymphohematopoietic progenitor cells. Exp Hematol (1986) 1.24
Breast cancer in the eastern province of Saudi Arabia. Med Oncol (1998) 1.16
Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N Engl J Med (1986) 1.14
Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol (2000) 1.11
Some guidelines for heparin therapy of venous thromboembolic disease. JAMA (1967) 1.09
Primary gastric non-Hodgkin's lymphoma: clinical features, management, and prognosis of 185 patients with diffuse large B-cell lymphoma. Ann Oncol (1999) 1.07
Tumor-promoting phorbol esters stimulate hematopoietic colony formation in vitro. Science (1980) 1.05
Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant (2010) 1.04
Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients. Head Neck (2001) 1.03
Interaction of prostaglandins E1 and E2 in regulation of cyclic-AMP and aggregation in human platelets: evidence for a common prostaglandin receptor. J Lab Clin Med (1974) 0.98
Growth factor and patient-adapted use of plerixafor is superior to CY and growth factor for autologous hematopoietic stem cells mobilization. Bone Marrow Transplant (2010) 0.96
Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst (1991) 0.96
Activity of trifluorothymidine against cytomegalovirus. Antimicrob Agents Chemother (1981) 0.94
Antigenic analysis of hematopoiesis. I. Expression of the My-1 granulocyte surface antigen on human marrow cells and leukemic cell lines. Blood (1983) 0.93
Platelet aggregation in patients with Laennec's cirrhosis of the liver. N Engl J Med (1967) 0.93
Effect of several antiviral agents on human lymphocyte functions and marrow progenitor cell proliferation. Antimicrob Agents Chemother (1983) 0.92
Pseudomonas aeruginosa exotoxin A inhibits proliferation of human bone marrow progenitor cells in vitro. Infect Immun (1982) 0.92
Nutritional support of bone marrow transplant recipients: a prospective, randomized clinical trial comparing total parenteral nutrition to an enteral feeding program. Cancer Res (1987) 0.91
Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure. Bone Marrow Transplant (2012) 0.90
Case report: isoimmune inhibition of erythropoiesis following ABO-incompatible bone marrow transplantation. Am J Med Sci (1991) 0.89
Tumor-promoting phorbol esters stimulate myelopoiesis and suppress erythropoiesis in cultures of mouse bone marrow cells. Proc Natl Acad Sci U S A (1981) 0.89
Autologous bone marrow transplantation in acute leukemia: a phase I study of in vitro treatment of marrow with 4-hydroperoxycyclophosphamide to purge tumor cells. Blood (1985) 0.88
Dye-mediated photolysis of normal and neoplastic hematopoietic cells. Leuk Res (1987) 0.87
Regulation of hematopoiesis: helper and suppressor influences of the thymus. Blood (1980) 0.85
Evidence-based medicine for the new millennium: Critical appraisal and pragmatic approach. Ann Saudi Med (2007) 0.84
The influence of serum tumor necrosis factor-alpha and interleukin-6 concentrations on nonhematologic toxicity and hematologic recovery in patients with acute myelogenous leukemia. Exp Hematol (1995) 0.83
Regulation of myelopoiesis in vitro: partial replacement of colony-stimulating factors by tumor-promoting phorbol esters. Blood (1981) 0.83
Hematologic and cytogenetic remission of 5q-refractory anemia after syngeneic bone marrow transplantation. Am J Med (1986) 0.83
Carbenicillin-trimethoprim/sulfamethoxazole versus carbenicillin-gentamicin as empiric therapy of infection in granulocytopenic patients. A prospective, randomized, double-blind study. Am J Med (1980) 0.81
Autologous bone marrow transplant in a patient with sickle cell disease and diffuse large B-cell lymphoma. Transplant Proc (2003) 0.81
Disposition of folic acid and its metabolites: a comparison with leucovorin. Clin Pharmacol Ther (1994) 0.81
Phase I and pharmacologic study of a 3-hour infusion of paclitaxel followed by cisplatinum and 5-fluorouracil in patients with advanced solid tumors. Clin Cancer Res (1999) 0.81
Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial. Med Oncol (2000) 0.80
Monitoring heparin therapy with the activated partial thromboplastin time. Can Med Assoc J (1971) 0.80
The occurrence of a peripheral T-cell lymphoma in a chronically immunosuppressed renal transplant patient. Am J Surg Pathol (1988) 0.80
Medical therapy of prostate cancer. J S C Med Assoc (1994) 0.79
High complete pathological response in locally advanced breast cancer using paclitaxel and cisplatin. Breast Cancer Res Treat (2000) 0.79
Immunobiology of allogeneic peripheral blood mononuclear cells mobilized with granulocyte-colony stimulating factor. Bone Marrow Transplant (2000) 0.78
Nutritional assessment by isotope dilution analysis of body composition. Am J Clin Nutr (1984) 0.78
Transfusion management of an IgA deficient patient with anti-IgA and incidental correction of IgA deficiency after allogeneic bone marrow transplantation. Am J Hematol (1998) 0.78
Energy requirements of parenterally fed bone marrow transplant recipients. JPEN J Parenter Enteral Nutr (1985) 0.78
Cellular glutathione as a protective agent against 4-hydroperoxycyclophosphamide cytotoxicity in K-562 cells. Cancer Chemother Pharmacol (1990) 0.78
Comparative effects o ADP and thrombin in producing stasis thrombosis. Thromb Diath Haemorrh (1967) 0.77
Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines. Cancer Res (1991) 0.77
Activation of intravascular coagulation by collagen. Proc Soc Exp Biol Med (1966) 0.77
Platelet survival in patients with prosthetic heart valves. Am J Cardiol (1974) 0.77
Regulation of cyclic AMP levels and aggregation in human platelets by prostaglandin E . J Lab Clin Med (1973) 0.76
Consultation letters as a method for assessing in-training performance in a department of medicine. Eval Health Prof (1988) 0.76
Human multilineage progenitor cell sensitivity to 4-hydroperoxycyclophosphamide. Exp Hematol (1985) 0.76
Insensitivity of actin FS in the detection of nonspecific inhibitors. Arch Pathol Lab Med (1994) 0.75
Editorial: Hypercoagulability--1974. Can Med Assoc J (1974) 0.75
Tumor-promoting phorbol esters support the in vitro proliferation of murine pluripotent hematopoietic stem cells. J Clin Invest (1989) 0.75
Adverse effects of nutritional deprivation on transplanted hematopoietic cells. Exp Hematol (1979) 0.75
Parenteral trimethoprim-sulfamethoxazole and carbenicillin as empiric therapy for neutropenic patients with cancer. Rev Infect Dis (1982) 0.75
Synergism between 4-hydroperoxycyclophosphamide and cisplatin: importance of incubation sequence and measurement of cisplatin accumulation. Biochem Pharmacol (1990) 0.75
Phorbol ester-stimulated murine myelopoiesis: role of colony-stimulating factors. J Cell Physiol (1983) 0.75
A new design for randomized trials. N Engl J Med (1979) 0.75
Determination of sulphinpyrazone in patient plasma by gas chromatography. Thromb Res (1978) 0.75
Fatty acid breath test values in the malabsorption range in cancer patients. Nutr Cancer (1982) 0.75
Effects of aspirin and sulfinpyrazone on platelet prostaglandin synthesis. Adv Exp Med Biol (1977) 0.75
CD34+ and CD33+ stem cells: predictors of hematologic recovery? Prog Clin Biol Res (1992) 0.75
Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update. Prog Clin Biol Res (1990) 0.75
A phase II trial of high-dose cytarabine and cisplatin in previously untreated non-small cell carcinoma of the lung. A Piedmont Oncology Association Study. Cancer (1990) 0.75
Immunotherapy of acute myeloid leukemia. Curr Pharm Biotechnol (2001) 0.75
Abnormal fatty acid breath tests in cancer patients, with nutritional correlation. Cancer (1982) 0.75
Epinephrine potentiation of platelet aggregation: its effect on death from experimental pulmonaryeembolism. J Lab Clin Med (1968) 0.75
Breast cancer. Trans Assoc Life Insur Med Dir Am (1989) 0.75
In vitro synergism of 4-hydroperoxycyclophosphamide and cisplatin: relevance for bone marrow purging. Cancer Chemother Pharmacol (1989) 0.75